retatrutide clinical data Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide is one of the

We dont have evidence that giving a healthy human an injectable GLP-1 agonist will directly increase their VO2max or endurance capacity and in fact, what limited human data we have suggests no performance boost

Key resources include the bacteriostatic water mixing guide for tirzepatide and the equivalent guide for retatrutide

*Correspondence: Roberta Poli, [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

If the insurance company requires further clarification or documentation, the approval process can take longer

Research shows that regular physical activity also supports appetite regulation and metabolic health, making it one of the most effective natural ways to support GLP-1 alongside a balanced diet